{"success":true,"data":{"pressRelease":{"id":"132856","rtpr_id":"nGNX5vBbxS","ticker":"SPRY","exchange":"NASDAQ","all_tickers":["SPRY"],"title":"SPRY DEADLINE: SueWallSt Reminds ARS Pharmaceuticals Inc. Investors of Upcoming Securities Class Action Deadline","author":"Globe Newswire","published_at":"2026-09-01T14:17:00.110Z","article_body":"NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- SueWallSt reminds purchasers of\nARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities of a pending securities\nclass action brought on behalf of investors who acquired shares between March\n9, 2026 and June 24, 2026. Find out if you might qualify for recovery\n(https://www.globenewswire.com/Tracker?data=VFeAaMt2pVzKpc3VVT_5P82DGkimAd-uIVWzsxfLD2cwKovpLtLf7WICOTQe6C3p6qOAu7GjMpjAmWlLBamvSMuOxvRkR2AbkWlC9YENMFklmy3CW89eQu3lPKl0ID78Lztr7BOVE0yt5I8-R43V6SsuVWWg5O1c1qAi6Oy28fZZvkpSBg6b0VWf6z_DUurQ42xQUBPzh9RICsEWF04ljDfdy7cirhV5Ls9lzuxCoXo=).\nYou may also contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com or (888)\nSueWallSt.\n\nSPRY shares closed at $10.54 on June 24, 2026 and fell to $8.02 the following\nsession, a one-day decline of $2.52 per share, or 23.9%. Motions for lead\nplaintiff must be filed with the Court by October 5, 2026.\n\nThe Formulary Access Strategy at the Center of the Case\n\nneffy's commercial trajectory depended on one operational objective: removing\nprior authorization requirements at the remaining major pharmacy benefit\nmanager. As pleaded, the Company entered 2026 with roughly 93% overall\ncommercial coverage but only about 57% of covered lives able to obtain neffy\nwithout a prior authorization, and approval rates of roughly 55% where a PA\nwas required. Plaintiffs allege that management repeatedly framed a CVS\nCaremark formulary addition, targeted for a July 1, 2026 effective date, as\nthe fix for that administrative friction.\n\nWhat the Action Contends Was Not Disclosed\n\nThe action contends that while investors were told the CVS proposal was in the\nfinal stages of the approval process, the risk that the decision could slip\npast the July 1 cycle was not adequately conveyed. On June 24, 2026, after the\nmarket closed, ARS announced that no new commercial formulary additions or\ncoverage decisions had been issued for neffy in the July 1, 2026 cycle, and\nthat a decision was reserved until January 2027, leaving the summer and\nback-to-school seasons without expanded coverage.\n\nAlleged Access Failures Investors Are Reviewing\n* Prior authorization removal at the largest remaining PBM was presented as a\nnear-term commercial catalyst\n* Approximately 43% of covered lives allegedly remained subject to PA friction\nentering the class period\n* Roughly 45% of PA submissions were not approved, according to figures cited\nin the action\n* A retail conversion program converting denied claims to a $199 cash price\nwas positioned as a bridge, not a substitute for formulary coverage\n* The reserved decision pushed any unrestricted access to a January 2027 cycle\n* Shares repriced by $2.52 on the disclosure\n\"The complaint raises serious questions about whether investors received\naccurate information regarding the status of a formulary decision that the\nCompany itself identified as central to neffy's commercial growth,\" -- Joseph\nE. Levi, Esq.\n\nSubmit your information now\n(https://www.globenewswire.com/Tracker?data=vLKglNXvb19L4IzY67KT3ql2vaqpTTbFk8KTV92TCSLUAks5yAK0cxvd-3ZNyzQA1ZAH5q2wkg9Lb6slCds5wbQ9THaZBptT3e3AVb-g6ok4r2zPSxKmSxxzMCLsHfjBeHtVQ7k9CzAjn0ExAZabAEKXEPkYLrisMFfytl_tm-g4jyHbu1LFfAxWwOu1jv9bmNltBbKCk-bqMT2XDo3g2A==)\nor call (888) SueWallSt.\n\nWHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky\nLLP has established itself as a nationally-recognized securities litigation\nfirm that has secured hundreds of millions of dollars for aggrieved\nshareholders and built a track record of winning high-stakes cases. The firm\nhas extensive expertise representing investors in complex securities\nlitigation and a team of over 70 employees to serve our clients. For seven\nyears in a row, Levi & Korsinsky has ranked in ISS Securities Class Action\nServices' Top 50 Report as one of the top securities litigation firms in the\nUnited States.\n\nFrequently Asked Questions About the SPRY Lawsuit\n\nQ: What is the SPRY class action lawsuit about? A: A securities class action\nhas been filed against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) alleging\nmaterially false and misleading statements between March 9, 2026 and June 24,\n2026. Shares fell approximately 23.9% after the Company disclosed that no new\ncommercial formulary additions or coverage decisions were issued for neffy in\nthe July 1, 2026 cycle and that CVS Caremark reserved its decision until\nJanuary 2027. Investors who purchased shares during the Class Period and\nsuffered losses may be eligible to seek compensation.\n\nQ: Who is eligible to join the SPRY investor lawsuit? A: Investors who\npurchased SPRY stock or securities between March 9, 2026 and June 24, 2026 and\nsuffered financial losses may be eligible. Eligibility is based on purchase\ndate and documented losses -- not on whether you still hold the shares.\n\nQ: What court was the SPRY class action filed in? A: The case was filed in the\nUnited States District Court for the Southern District of California, governed\nby the Private Securities Litigation Reform Act of 1995.\n\nQ: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the\ninvestor appointed by the court to represent the entire class. Lead plaintiffs\nare typically investors with the largest documented losses. Being appointed\ndoes not increase individual recovery but gives direct oversight of how the\ncase is run.\n\nQ: What do SPRY investors need to do right now? A: Gather brokerage records\nincluding purchase dates, share quantities, and prices paid. Contact Levi &\nKorsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or\n(212) 363-7500. No immediate action is required to remain eligible as an\nabsent class member.\n\nQ: What if I already sold my SPRY shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthe shares. Investors who bought during the Class Period and sold at a loss\nmay still be eligible to participate.\n\nQ: What does it cost me to participate? A: There is no upfront cost to contact\nthe firm. Securities class actions are generally handled on a pure contingency\nbasis. No upfront fees, no retainer, and no out-of-pocket costs. Any\nattorneys' fees and expenses awarded to class counsel are subject to court\napproval.\n\nQ: Do I need to go to court or give testimony? A: No. The overwhelming\nmajority of class members never appear in court or give depositions. If there\nis a settlement or recovery, eligible class members generally submit a claim\nform to seek their portion.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@SueWallSt.com\nTel: (888) SueWallSt\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5vBbxS","title":"SPRY DEADLINE: SueWallSt Reminds ARS Pharmaceuticals Inc. Investors of Upcoming Securities Class Action Deadline","author":"Globe Newswire","ticker":"SPRY","created":"2026-09-01T14:17:00.110Z","tickers":["SPRY"],"exchange":"NASDAQ","article_body":"NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- SueWallSt reminds purchasers of\nARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities of a pending securities\nclass action brought on behalf of investors who acquired shares between March\n9, 2026 and June 24, 2026. Find out if you might qualify for recovery\n(https://www.globenewswire.com/Tracker?data=VFeAaMt2pVzKpc3VVT_5P82DGkimAd-uIVWzsxfLD2cwKovpLtLf7WICOTQe6C3p6qOAu7GjMpjAmWlLBamvSMuOxvRkR2AbkWlC9YENMFklmy3CW89eQu3lPKl0ID78Lztr7BOVE0yt5I8-R43V6SsuVWWg5O1c1qAi6Oy28fZZvkpSBg6b0VWf6z_DUurQ42xQUBPzh9RICsEWF04ljDfdy7cirhV5Ls9lzuxCoXo=).\nYou may also contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com or (888)\nSueWallSt.\n\nSPRY shares closed at $10.54 on June 24, 2026 and fell to $8.02 the following\nsession, a one-day decline of $2.52 per share, or 23.9%. Motions for lead\nplaintiff must be filed with the Court by October 5, 2026.\n\nThe Formulary Access Strategy at the Center of the Case\n\nneffy's commercial trajectory depended on one operational objective: removing\nprior authorization requirements at the remaining major pharmacy benefit\nmanager. As pleaded, the Company entered 2026 with roughly 93% overall\ncommercial coverage but only about 57% of covered lives able to obtain neffy\nwithout a prior authorization, and approval rates of roughly 55% where a PA\nwas required. Plaintiffs allege that management repeatedly framed a CVS\nCaremark formulary addition, targeted for a July 1, 2026 effective date, as\nthe fix for that administrative friction.\n\nWhat the Action Contends Was Not Disclosed\n\nThe action contends that while investors were told the CVS proposal was in the\nfinal stages of the approval process, the risk that the decision could slip\npast the July 1 cycle was not adequately conveyed. On June 24, 2026, after the\nmarket closed, ARS announced that no new commercial formulary additions or\ncoverage decisions had been issued for neffy in the July 1, 2026 cycle, and\nthat a decision was reserved until January 2027, leaving the summer and\nback-to-school seasons without expanded coverage.\n\nAlleged Access Failures Investors Are Reviewing\n* Prior authorization removal at the largest remaining PBM was presented as a\nnear-term commercial catalyst\n* Approximately 43% of covered lives allegedly remained subject to PA friction\nentering the class period\n* Roughly 45% of PA submissions were not approved, according to figures cited\nin the action\n* A retail conversion program converting denied claims to a $199 cash price\nwas positioned as a bridge, not a substitute for formulary coverage\n* The reserved decision pushed any unrestricted access to a January 2027 cycle\n* Shares repriced by $2.52 on the disclosure\n\"The complaint raises serious questions about whether investors received\naccurate information regarding the status of a formulary decision that the\nCompany itself identified as central to neffy's commercial growth,\" -- Joseph\nE. Levi, Esq.\n\nSubmit your information now\n(https://www.globenewswire.com/Tracker?data=vLKglNXvb19L4IzY67KT3ql2vaqpTTbFk8KTV92TCSLUAks5yAK0cxvd-3ZNyzQA1ZAH5q2wkg9Lb6slCds5wbQ9THaZBptT3e3AVb-g6ok4r2zPSxKmSxxzMCLsHfjBeHtVQ7k9CzAjn0ExAZabAEKXEPkYLrisMFfytl_tm-g4jyHbu1LFfAxWwOu1jv9bmNltBbKCk-bqMT2XDo3g2A==)\nor call (888) SueWallSt.\n\nWHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky\nLLP has established itself as a nationally-recognized securities litigation\nfirm that has secured hundreds of millions of dollars for aggrieved\nshareholders and built a track record of winning high-stakes cases. The firm\nhas extensive expertise representing investors in complex securities\nlitigation and a team of over 70 employees to serve our clients. For seven\nyears in a row, Levi & Korsinsky has ranked in ISS Securities Class Action\nServices' Top 50 Report as one of the top securities litigation firms in the\nUnited States.\n\nFrequently Asked Questions About the SPRY Lawsuit\n\nQ: What is the SPRY class action lawsuit about? A: A securities class action\nhas been filed against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) alleging\nmaterially false and misleading statements between March 9, 2026 and June 24,\n2026. Shares fell approximately 23.9% after the Company disclosed that no new\ncommercial formulary additions or coverage decisions were issued for neffy in\nthe July 1, 2026 cycle and that CVS Caremark reserved its decision until\nJanuary 2027. Investors who purchased shares during the Class Period and\nsuffered losses may be eligible to seek compensation.\n\nQ: Who is eligible to join the SPRY investor lawsuit? A: Investors who\npurchased SPRY stock or securities between March 9, 2026 and June 24, 2026 and\nsuffered financial losses may be eligible. Eligibility is based on purchase\ndate and documented losses -- not on whether you still hold the shares.\n\nQ: What court was the SPRY class action filed in? A: The case was filed in the\nUnited States District Court for the Southern District of California, governed\nby the Private Securities Litigation Reform Act of 1995.\n\nQ: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the\ninvestor appointed by the court to represent the entire class. Lead plaintiffs\nare typically investors with the largest documented losses. Being appointed\ndoes not increase individual recovery but gives direct oversight of how the\ncase is run.\n\nQ: What do SPRY investors need to do right now? A: Gather brokerage records\nincluding purchase dates, share quantities, and prices paid. Contact Levi &\nKorsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or\n(212) 363-7500. No immediate action is required to remain eligible as an\nabsent class member.\n\nQ: What if I already sold my SPRY shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthe shares. Investors who bought during the Class Period and sold at a loss\nmay still be eligible to participate.\n\nQ: What does it cost me to participate? A: There is no upfront cost to contact\nthe firm. Securities class actions are generally handled on a pure contingency\nbasis. No upfront fees, no retainer, and no out-of-pocket costs. Any\nattorneys' fees and expenses awarded to class counsel are subject to court\napproval.\n\nQ: Do I need to go to court or give testimony? A: No. The overwhelming\nmajority of class members never appear in court or give depositions. If there\nis a settlement or recovery, eligible class members generally submit a claim\nform to seek their portion.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@SueWallSt.com\nTel: (888) SueWallSt\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-01T14:17:00.150540808Z","server_sent_at_ms":1788272220150},"received_at":"2026-09-01T14:17:00.357Z","source_url":null},"analysis":{"id":"121747","press_release_id":"132856","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"SueWallSt, powered by Levi & Korsinsky LLP, reminded ARS Pharmaceuticals investors of the October 5, 2026 deadline to file lead plaintiff motions in a pending securities class action. The lawsuit covers shareholders who purchased SPRY securities between March 9, 2026 and June 24, 2026.\n\nThe allegations focus on claims that ARS misled investors regarding the commercial trajectory of its product neffy, specifically concerning a CVS Caremark formulary addition. The complaint states the company failed to adequately convey the risk that the formulary decision would slip past the July 1, 2026 target date.\n\nShares reportedly fell $2.52, or 23.9%, to $8.02 on June 25, 2026, after the company disclosed no new formulary additions for the July cycle and that CVS Caremark reserved its decision until January 2027.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"The complaint raises serious questions about whether investors received accurate information regarding the status of a formulary decision that the Company itself identified as central to neffy's commercial growth,\" -- Joseph E. Levi, Esq.","namedEntities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"Attorney at SueWallSt / Levi & Korsinsky LLP"}],"products":["neffy"],"companies":[{"name":"ARS Pharmaceuticals Inc.","ticker":"SPRY","relationship":"defendant"},{"name":"SueWallSt","relationship":"plaintiff law firm / marketing brand"},{"name":"Levi & Korsinsky LLP","relationship":"plaintiff law firm"},{"name":"CVS Caremark","relationship":"mentioned"}],"dollarAmounts":[{"amount":"$10.54","context":"SPRY closing price on June 24, 2026"},{"amount":"$8.02","context":"SPRY closing price the following session"},{"amount":"$2.52","context":"one-day decline per share"},{"amount":"$199","context":"retail conversion cash price"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by SueWallSt (powered by Levi & Korsinsky). No new disclosure from the issuer; no certified class or settlement announced. Standard lead-plaintiff deadline reminder."},"tickerRelevance":{"others":[],"primary":"SPRY"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"SueWallSt, powered by Levi & Korsinsky LLP, reminded ARS Pharmaceuticals investors of the October 5, 2026 deadline to file lead plaintiff motions in a pending securities class action. The lawsuit covers shareholders who purchased SPRY securities between March 9, 2026 and June 24, 2026.\n\nThe allegations focus on claims that ARS misled investors regarding the commercial trajectory of its product neffy, specifically concerning a CVS Caremark formulary addition. The complaint states the company failed to adequately convey the risk that the formulary decision would slip past the July 1, 2026 target date.\n\nShares reportedly fell $2.52, or 23.9%, to $8.02 on June 25, 2026, after the company disclosed no new formulary additions for the July cycle and that CVS Caremark reserved its decision until January 2027.","key_figures":{},"named_entities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"Attorney at SueWallSt / Levi & Korsinsky LLP"}],"products":["neffy"],"companies":[{"name":"ARS Pharmaceuticals Inc.","ticker":"SPRY","relationship":"defendant"},{"name":"SueWallSt","relationship":"plaintiff law firm / marketing brand"},{"name":"Levi & Korsinsky LLP","relationship":"plaintiff law firm"},{"name":"CVS Caremark","relationship":"mentioned"}],"dollarAmounts":[{"amount":"$10.54","context":"SPRY closing price on June 24, 2026"},{"amount":"$8.02","context":"SPRY closing price the following session"},{"amount":"$2.52","context":"one-day decline per share"},{"amount":"$199","context":"retail conversion cash price"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-01T17:18:01.360Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":95316,"modelName":"glm-4.7"}}